Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The evidence of improved coordination transferring to Parkinson would be a great quality of life improvement. Now we'll have to see if 273 works alone in tampering tremors.
BTW are you invested. Just curious.
"I do have other biotechs and I think cynicism is a reasonable starting point for biotech in general".
Interesting, I see no other cynicism other then AVXL in your posting history. I like my cynicism served with a side of honesty.
Even if scores are below Otezla there would still be a good market for Prurisol due to it being safe and fast acting compared to others.
I would actually prefer a sale of Prurisol. Equivalent scores faster results plus lower side effects vs Otezla easily 6 BIllion. If scores range 90+ like biologic's it takes over market share and gets 10 plus Billion when comparing sales. It's all based on scoring.
Don't forget to add Leo and big pharma.
I fully agree with your super responder response. Seems they are getting to the bottom of it.
Genome marking Missling mentioned may help them better understand the super responders.
Yes partnering would be the mother of all catalysts but I also believe great prurisol data will have a profound effect on raising share price ahead of any deal. B UP and OM will help bolster the franchise but what effect they have on share price early on is a wait and see. imo
Yes that's right they just opened a couple more sites. Thanks.
Design called for full study top-line results in 3Q2017. Could still happen.
It's double blind plus placebo with 189 participators, seems powered for a deal.
Up listing does not inoculate a small company from short articles that's for sure. Up listing this summer behind multiple great data results would give the company a good fundamental base.
I've seen this more times then I can count on small caps. On the IPIX saga Mako and Adam Furenstein purposely all but killed investor confidence. This stock has been beat down mercilessly and some have taken advantage of it.
Nice going.
Efficacy reported in the 200mg arm was clear. So clear was the results that it spurred design of the escalated Prurisol phase 2B trial.
Dr B thinks we can take out Otezla and capture that $2 Billion spot.
Prurisol is the real deal.
Scott I got to say this cc goes a lot deeper then simple if not negatively biased surface responses.
Now that was funny.
"looking to structure partnerships and joint-ventures should such opportunities present themselves.”
Got to say it's the first time I've seen joint venture used. Joint venture could be another small company joining forces together on a project.
From the start of the year..
"As conveyed by Cellceutix management in a presentation given at the 2017 Biotech Showcase held in San Francisco, CA, the company’s focus this year is on partnerships—identifying new opportunities as well as continuing discussions with companies already under Confidential Disclosure Agreement (CDA).
With a number of upcoming anticipated clinical milestones (see below), management is hopeful that partnerships can be struck in 2017 to help advance Cellceutix's pipeline of First-in-Class drug candidates—Prurisol, Kevetrin and Brilacidin—toward market approval".
CDA's in place so company will partner. Takes money to make money.
Sorry scott beat you to the rs ploy.
We'll see, I'm hoping this late in the trials we can move up organically.
made me laugh.
You know Leo said many times no reverse split.
The name change will be discussed at the upcoming live shareholder and investor conference call, to be held on Thursday, June 8, 2017, at 11am EDT. Senior Company management will be responding to recently posed questions submitted by email. Live call-in questions will also be addressed.
Yes even the shorts realize further good data will ensure a partnership. Can't wait to get past this nickel and dime stuff.
Shorts post less go back in hiding..
Red day so nothing new coming. geesh common Norchi deliver.
He's being a honest CEO when saying we MAY need more studies, it could be that we don't.
I read (heard) it as collaborations.
Yes he's knows things are lining up and he knows spending a little more will get them much more. Could it be p2a extension is going very well:)
Misslings loading the war chest to take this farther on his own for a larger upfront payment from BP. Definitely plans to partner.
The interviewer said investors want to know more. Are some institutions behind it.. maybe.
Bloomberg Sirius would have a larger audience then just a broadcast.
Now I wonder how large an audience he reached through Bloomberg radio.
Thanks, appreciate posting the dial in numbers.
Below are call-in details for the conference call:
Title: Shareholder and Investor Conference Call
Presentation Type: Audio Webcast
Event Date: Thursday, June 8, 2017, at 11am EDT
Call-in Numbers: 866-682-6100 / 862-255-5401
It's for share holders..
and investors.